Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as contributing factor

Jan E Drutz, MD
Section Editor
Teresa K Duryea, MD
Deputy Editor
Mary M Torchia, MD


The number of cases of autism spectrum disorder (ASD) in the United States and other countries has increased since the 1980s, largely due to changes in diagnostic criteria for ASD and increased awareness of ASD. The increased prevalence of ASD occurred at a time when the number of recommended childhood vaccines also increased, leading to a hypothesis that vaccines (eg, the measles, mumps, and rubella vaccine) or vaccine constituents (eg, thimerosal) contribute to the development of ASD and other chronic diseases. However, no scientific linkage between vaccines and ASD has been established.

The proposed association between vaccines or vaccine constituents and ASD and the evidence against the association will be discussed here. The epidemiology, pathogenesis, and clinical features of ASD are discussed separately. (See "Autism spectrum disorder: Terminology, epidemiology, and pathogenesis" and "Autism spectrum disorder: Clinical features".)


The number of cases of ASD in the United States and other countries has increased since the 1980s [1-9]. Rates of ASD in studies from the late 1990s are consistently greater than 10 per 10,000 compared with 4 to 5 per 10,000 in previous decades [10]. Active surveillance in the United States suggests a prevalence of approximately 1 in 68 eight-year-old children in the United States [9]. (See "Autism spectrum disorder: Terminology, epidemiology, and pathogenesis", section on 'Prevalence'.)

Whether or not the actual incidence of ASD has increased is unclear. Comparing studies with different case definitions, methods of case finding, and sample populations is problematic unless there is rigorous control for these variables. Systematic reviews of the epidemiologic studies suggest that changes in case definitions and increased awareness account for much of the increased prevalence [10-12].


The real or perceived increase in ASD cases occurred at a time when the number of recommended childhood vaccines also increased (to include Haemophilus influenza type b, hepatitis B, varicella, pneumococcal, and influenza vaccines, as well as a second dose of the measles, mumps, and rubella [MMR] vaccine). (See "Standard immunizations for children and adolescents".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Feb 2017. | This topic last updated: Wed Mar 08 00:00:00 GMT+00:00 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Department of Developmental Services. Changes in the population of persons with autism and pervasive developmental disorders in California's developmental services system: 1987 through 1998. A Report to the Legislature. California Health and Human Services, March 1, 1999. http://www.dds.ca.gov/Autism/docs/autism_report_1999.pdf (Accessed on October 05, 2011).
  2. Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JAMA 2001; 285:1183.
  3. Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med 2002; 347:1477.
  4. Madsen KM, Lauritsen MB, Pedersen CB, et al. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics 2003; 112:604.
  5. Kaye JA, del Mar Melero-Montes M, Jick H. Mumps, measles, and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001; 322:460.
  6. Yeargin-Allsopp M, Rice C, Karapurkar T, et al. Prevalence of autism in a US metropolitan area. JAMA 2003; 289:49.
  7. McCormick MC. The autism "epidemic": impressions from the perspective of immunization safety review. Ambul Pediatr 2003; 3:119.
  8. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators, Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014; 63:1.
  9. Christensen DL, Baio J, Van Naarden Braun K, et al. Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years--Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveill Summ 2016; 65:1.
  10. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65:591.
  11. Wing L, Potter D. The epidemiology of autistic spectrum disorders: is the prevalence rising? Ment Retard Dev Disabil Res Rev 2002; 8:151.
  12. Shattuck PT. The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education. Pediatrics 2006; 117:1028.
  13. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998; 351:637.
  14. Wakefield AJ, Montgomery SM. Autism, viral infection and measles-mumps-rubella vaccination. Isr Med Assoc J 1999; 1:183.
  15. Bernard S, Enayati A, Redwood L, et al. Autism: a novel form of mercury poisoning. Med Hypotheses 2001; 56:462.
  16. Bernard S, Enayati A, Roger H, et al. The role of mercury in the pathogenesis of autism. Mol Psychiatry 2002; 7 Suppl 2:S42.
  17. Geier MR, Geier DA. Thimerosal in childhood vaccines, neurodevelopment disorders and heart disease in the United States. J Am Physicians Surg 2003; 8:6.
  18. Geier MR, Geier DA. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med (Maywood) 2003; 228:660.
  19. Retraction--Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 2010; 375:445.
  20. Murch SH, Anthony A, Casson DH, et al. Retraction of an interpretation. Lancet 2004; 363:750.
  21. Deer B. How the case against the MMR vaccine was fixed. BMJ 2011; 342:c5347.
  22. Uhlmann V, Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol 2002; 55:84.
  23. Immunization Safety Review: Measles-Mumps-Rubella Vaccine and Autism, Stratton K, Wilson CB, McCormick MC (Eds), The National Academies Press, Washington, DC 2001.
  24. Offit, PA. Vaccines and autism. Immunization Action Coalition. www.immunize.org/catg.d/p2065.htm (Accessed on January 18, 2006).
  25. Fombonne E, Chakrabarti S. No evidence for a new variant of measles-mumps-rubella-induced autism. Pediatrics 2001; 108:E58.
  26. Offit PA, Coffin SE. Communicating science to the public: MMR vaccine and autism. Vaccine 2003; 22:1.
  27. Taylor B, Miller E, Lingam R, et al. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ 2002; 324:393.
  28. Immunization Safety Review: Vaccines and Autism. A report of the Institute of Medicine, National Academies Press, Washington, DC 2004.
  29. Evans AS. Causation and disease: a chronological journey. The Thomas Parran Lecture. 1978. Am J Epidemiol 1995; 142:1126.
  30. Kawashima H, Mori T, Kashiwagi Y, et al. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism. Dig Dis Sci 2000; 45:723.
  31. Fernell E, Fagerberg UL, Hellström PM. No evidence for a clear link between active intestinal inflammation and autism based on analyses of faecal calprotectin and rectal nitric oxide. Acta Paediatr 2007; 96:1076.
  32. Martin CM, Uhlmann V, Killalea A, et al. Detection of measles virus in children with ileo-colonic lymphoid nodular hyperplasia, enterocolitis and developmental disorder. Mol Psychiatry 2002; 7 Suppl 2:S47.
  33. Afzal MA, Ozoemena LC, O'Hare A, et al. Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK. J Med Virol 2006; 78:623.
  34. D'Souza Y, Fombonne E, Ward BJ. No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. Pediatrics 2006; 118:1664.
  35. Katz SL. Has the measles-mumps-rubella vaccine been fully exonerated? Pediatrics 2006; 118:1744.
  36. Cass H, Gringras P, March J, et al. Absence of urinary opioid peptides in children with autism. Arch Dis Child 2008; 93:745.
  37. Nagamitsu S, Matsuishi T, Kisa T, et al. CSF beta-endorphin levels in patients with infantile autism. J Autism Dev Disord 1997; 27:155.
  38. Gillberg C, Terenius L, Lönnerholm G. Endorphin activity in childhood psychosis. Spinal fluid levels in 24 cases. Arch Gen Psychiatry 1985; 42:780.
  39. Gillberg C, Terenius L, Hagberg B, et al. CSF beta-endorphins in childhood neuropsychiatric disorders. Brain Dev 1990; 12:88.
  40. Feldman HM, Kolmen BK, Gonzaga AM. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 1999; 38:587.
  41. Willemsen-Swinkels SH, Buitelaar JK, van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996; 39:1023.
  42. Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 1995; 58:203.
  43. Baird G, Pickles A, Simonoff E, et al. Measles vaccination and antibody response in autism spectrum disorders. Arch Dis Child 2008; 93:832.
  44. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999; 353:2026.
  45. Mäkelä A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 2002; 110:957.
  46. Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001; 19:3632.
  47. Patja A, Davidkin I, Kurki T, et al. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J 2000; 19:1127.
  48. Peltola H, Patja A, Leinikki P, et al. No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study. Lancet 1998; 351:1327.
  49. Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006; 118:e139.
  50. Uno Y, Uchiyama T, Kurosawa M, et al. Early exposure to the combined measles-mumps-rubella vaccine and thimerosal-containing vaccines and risk of autism spectrum disorder. Vaccine 2015; 33:2511.
  51. Jain A, Marshall J, Buikema A, et al. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA 2015; 313:1534.
  52. Jain A, Marshall J, Buikema A, et al. Correction of Description of MMR Vaccine Receipt Coding and Minor Errors in MMR Vaccine and Autism Study. JAMA 2016; 315:202.
  53. DeStefano F, Bhasin TK, Thompson WW, et al. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects: a population-based study in metropolitan atlanta. Pediatrics 2004; 113:259.
  54. Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet 2004; 364:963.
  55. Mrozek-Budzyn D, Kiełtyka A, Majewska R. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study. Pediatr Infect Dis J 2010; 29:397.
  56. Goin-Kochel RP, Mire SS, Dempsey AG, et al. Parental report of vaccine receipt in children with autism spectrum disorder: Do rates differ by pattern of ASD onset? Vaccine 2016; 34:1335.
  57. Uno Y, Uchiyama T, Kurosawa M, et al. The combined measles, mumps, and rubella vaccines and the total number of vaccines are not associated with development of autism spectrum disorder: the first case-control study in Asia. Vaccine 2012; 30:4292.
  58. Wilson K, Mills E, Ross C, et al. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Arch Pediatr Adolesc Med 2003; 157:628.
  59. Institute of Medicine of the National Academies. Measles, mumps, and rubella vaccine. In: Adverse Effects of Vaccines: Evidence and Causality, Stratton K, Ford A, Rusch E, Wright E. (Eds), National Academies Press, Washington, DC 2011. p.89.
  60. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol 1979; 110:105.
  61. Murphy TV, Gargiullo PM, Massoudi MS, et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001; 344:564.
  62. Miller E, Waight P, Farrington CP, et al. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001; 84:227.
  63. Uchiyama T, Kurosawa M, Inaba Y. MMR-vaccine and regression in autism spectrum disorders: negative results presented from Japan. J Autism Dev Disord 2007; 37:210.
  64. Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine 2014; 32:3623.
  65. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev 2012; :CD004407.
  66. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatry 2005; 46:572.
  67. Centers for Disease Control and Prevention (CDC). Summary of the joint statement on thimerosal in vaccines. American Academy of Family Physicians, American Academy of Pediatrics, Advisory Committee on Immunization Practices, Public Health Service. MMWR Morb Mortal Wkly Rep 2000; 49:622, 631.
  68. Miles JH, Takahashi TN. Lack of association between Rh status, Rh immune globulin in pregnancy and autism. Am J Med Genet A 2007; 143A:1397.
  69. Joint statement of the American Academy of Pediatrics (AAP) and the United States Public Health Service (USPHS). Pediatrics 1999; 104:568.
  70. Thimerosal in vaccines--An interim report to clinicians. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Environmental Health. Pediatrics 1999; 104:570.
  71. Redwood L, Bernard S, Brown D. Predicted mercury concentrations in hair from infant immunizations: cause for concern. Neurotoxicology 2001; 22:691.
  72. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001; 107:1147.
  73. Cooper LZ, Katz SL. Ban on thimerosal in draft treaty on mercury: why the AAP's position in 2012 is so important. Pediatrics 2013; 131:152.
  74. Orenstein WA, Paulson JA, Brady MT, et al. Global vaccination recommendations and thimerosal. Pediatrics 2013; 131:149.
  75. Global Advisory Committee on Vaccine Safety, June 2012. Wkly Epidemiol Rec 2012; 87:281.
  76. Meeting of Global Advisory Committee on Vaccine Safety, 18-19 June 2008. Wkly Epidemiol Rec 2008; 83:287.
  77. Clarkson TW, Magos L, Myers GJ. The toxicology of mercury--current exposures and clinical manifestations. N Engl J Med 2003; 349:1731.
  78. Study fails to show a connection between thimerosal and autism. American Academy of Pediatrics. Posted May 16, 2003. www.cispimmunize.org/pro/doc/Geiersummary.doc (Accessed on January 18, 2006).
  79. Magos L. Review on the toxicity of ethylmercury, including its presence as a preservative in biological and pharmaceutical products. J Appl Toxicol 2001; 21:1.
  80. Smith JC, Farris FF. Methyl mercury pharmacokinetics in man: a reevaluation. Toxicol Appl Pharmacol 1996; 137:245.
  81. Magos L, Brown AW, Sparrow S, et al. The comparative toxicology of ethyl- and methylmercury. Arch Toxicol 1985; 57:260.
  82. Pichichero ME, Gentile A, Giglio N, et al. Mercury levels in premature and low birth weight newborn infants after receipt of thimerosal-containing vaccines. J Pediatr 2009; 155:495.
  84. Amin-Zaki L, Majeed MA, Greenwood MR, et al. Methylmercury poisoning in the Iraqi suckling infant: a longitudinal study over five years. J Appl Toxicol 1981; 1:210.
  85. Matheson DS, Clarkson TW, Gelfand EW. Mercury toxicity (acrodynia) induced by long-term injection of gammaglobulin. J Pediatr 1980; 97:153.
  86. Rohyans J, Walson PD, Wood GA, MacDonald WA. Mercury toxicity following merthiolate ear irrigations. J Pediatr 1984; 104:311.
  87. Pfab R, Mückter H, Roider G, Zilker T. Clinical course of severe poisoning with thiomersal. J Toxicol Clin Toxicol 1996; 34:453.
  88. HAY WJ, RICKARDS AG, McMENEMEY WH, CUMINGS JN. Organic mercurial encephalopathy. J Neurol Neurosurg Psychiatry 1963; 26:199.
  89. Cinca I, Dumitrescu I, Onaca P, et al. Accidental ethyl mercury poisoning with nervous system, skeletal muscle, and myocardium injury. J Neurol Neurosurg Psychiatry 1980; 43:143.
  90. Myers GJ, Davidson PW, Cox C, et al. Prenatal methylmercury exposure from ocean fish consumption in the Seychelles child development study. Lancet 2003; 361:1686.
  91. Davidson PW, Kost J, Myers GJ, et al. Methylmercury and neurodevelopment: reanalysis of the Seychelles Child Development Study outcomes at 66 months of age. JAMA 2001; 285:1291.
  92. Grandjean P, Weihe P, White RF, et al. Cognitive deficit in 7-year-old children with prenatal exposure to methylmercury. Neurotoxicol Teratol 1997; 19:417.
  93. Sørensen N, Murata K, Budtz-Jørgensen E, et al. Prenatal methylmercury exposure as a cardiovascular risk factor at seven years of age. Epidemiology 1999; 10:370.
  94. Murata K, Weihe P, Budtz-Jørgensen E, et al. Delayed brainstem auditory evoked potential latencies in 14-year-old children exposed to methylmercury. J Pediatr 2004; 144:177.
  95. Myers GJ, Davidson PW, Cox C, et al. Twenty-seven years studying the human neurotoxicity of methylmercury exposure. Environ Res 2000; 83:275.
  96. Aschner M. Mercury toxicity. J Pediatr 2001; 138:450.
  97. Kerper LE, Ballatori N, Clarkson TW. Methylmercury transport across the blood-brain barrier by an amino acid carrier. Am J Physiol 1992; 262:R761.
  98. Nelson KB, Bauman ML. Thimerosal and autism? Pediatrics 2003; 111:674.
  99. Stajich GV, Lopez GP, Harry SW, Sexson WR. Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants. J Pediatr 2000; 136:679.
  100. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 2002; 360:1737.
  101. Pichichero ME, Gentile A, Giglio N, et al. Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics 2008; 121:e208.
  102. Mayo Medical Laboratories. Blood Mercury. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/8618 (Accessed on February 26, 2017).
  103. Mitkus RJ, King DB, Walderhaug MO, Forshee RA. A comparative pharmacokinetic estimate of mercury in U.S. Infants following yearly exposures to inactivated influenza vaccines containing thimerosal. Risk Anal 2014; 34:735.
  104. US Food & Drug Administration. Thimerosal in Vaccines. https://www.fda.gov/biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm096228.htm#guid (Accessed on February 23, 2017).
  105. Stratton K, Gable A, McCormick MC. Immunization Safety Review: Thimerosal-Containing Vaccines and Neurodevelopmental Disorders, National Academy Press, Washington, DC 2001.
  106. Cave S. Mercury in medicine: Are we taking unnecessary risks? Hearing before the Committee on Government Reform, US House of Representatives, July 18, 2000.
  107. Bradstreet J. Autism - Why the increased rates? One-year update. Hearing before the Committee on Government Reform, US House of Representatives, April 25, 2001. Available at: www.gpo.gov/fdsys/pkg/CHRG-107hhrg76856/pdf/CHRG-107hhrg76856.pdf (Accessed on April 05, 2012).
  108. Skalny AV, Simashkova NV, Klyushnik TP, et al. Hair toxic and essential trace elements in children with autism spectrum disorder. Metab Brain Dis 2017; 32:195.
  109. Mohamed Fel B, Zaky EA, El-Sayed AB, et al. Assessment of Hair Aluminum, Lead, and Mercury in a Sample of Autistic Egyptian Children: Environmental Risk Factors of Heavy Metals in Autism. Behav Neurol 2015; 2015:545674.
  110. Mostafa GA, Bjørklund G, Urbina MA, Al-Ayadhi LY. The levels of blood mercury and inflammatory-related neuropeptides in the serum are correlated in children with autism spectrum disorder. Metab Brain Dis 2016; 31:593.
  111. Geier DA, Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr Rehabil 2003; 6:97.
  112. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 2004; 114:793.
  113. Gadad BS, Li W, Yazdani U, et al. Administration of thimerosal-containing vaccines to infant rhesus macaques does not result in autism-like behavior or neuropathology. Proc Natl Acad Sci U S A 2015; 112:12498.
  114. Kark RA, Poskanzer DC, Bullock JD, Boylen G. Mercury poisoning and its treatment with N-acetyl-D,L-penicillamine. N Engl J Med 1971; 285:10.
  115. Eto K. Minamata disease. Neuropathology 2000; 20 Suppl:S14.
  116. Korogi Y, Takahashi M, Hirai T, et al. Representation of the visual field in the striate cortex: comparison of MR findings with visual field deficits in organic mercury poisoning (Minamata disease). AJNR Am J Neuroradiol 1997; 18:1127.
  117. Torres AD, Rai AN, Hardiek ML. Mercury intoxication and arterial hypertension: report of two patients and review of the literature. Pediatrics 2000; 105:E34.
  118. Boyd AS, Seger D, Vannucci S, et al. Mercury exposure and cutaneous disease. J Am Acad Dermatol 2000; 43:81.
  119. Dantzig PI. A new cutaneous sign of mercury poisoning? J Am Acad Dermatol 2003; 49:1109.
  120. Fuortes LJ, Weismann DN, Graeff ML, et al. Immune thrombocytopenia and elemental mercury poisoning. J Toxicol Clin Toxicol 1995; 33:449.
  121. Maghazaji HI. Psychiatric aspects of methylmercury poisoning. J Neurol Neurosurg Psychiatry 1974; 37:954.
  122. Ross WD, Sholiton MC. Specificity of psychiatric manifestations in relation to neurotoxic chemicals. Acta Psychiatr Scand Suppl 1983; 303:100.
  123. Powell TJ. Chronic neurobehavioural effects of mercury poisoning on a group of Zulu chemical workers. Brain Inj 2000; 14:797.
  124. Ramirez GB, Cruz MC, Pagulayan O, et al. The Tagum study I: analysis and clinical correlates of mercury in maternal and cord blood, breast milk, meconium, and infants' hair. Pediatrics 2000; 106:774.
  125. Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA 2003; 290:337.
  126. Davidovitch M, Patterson B, Gartside P. Head circumference measurements in children with autism. J Child Neurol 1996; 11:389.
  127. Lainhart JE, Piven J, Wzorek M, et al. Macrocephaly in children and adults with autism. J Am Acad Child Adolesc Psychiatry 1997; 36:282.
  128. Stevenson RE, Schroer RJ, Skinner C, et al. Autism and macrocephaly. Lancet 1997; 349:1744.
  129. Nierenberg DW, Nordgren RE, Chang MB, et al. Delayed cerebellar disease and death after accidental exposure to dimethylmercury. N Engl J Med 1998; 338:1672.
  130. Kemper TL, Bauman ML. Neuropathology of infantile autism. Mol Psychiatry 2002; 7 Suppl 2:S12.
  131. Courchesne E, Karns CM, Davis HR, et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology 2001; 57:245.
  132. Ritvo ER, Freeman BJ, Scheibel AB, et al. Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSAC Autopsy Research Report. Am J Psychiatry 1986; 143:862.
  133. Bailey A, Luthert P, Dean A, et al. A clinicopathological study of autism. Brain 1998; 121 ( Pt 5):889.
  134. Stoner R, Chow ML, Boyle MP, et al. Patches of disorganization in the neocortex of children with autism. N Engl J Med 2014; 370:1209.
  135. Stehr-Green P, Tull P, Stellfeld M, et al. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med 2003; 25:101.
  136. Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 2003; 112:1039.
  137. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA 2003; 290:1763.
  138. Heron J, Golding J, ALSPAC Study Team. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association. Pediatrics 2004; 114:577.
  139. Andrews N, Miller E, Grant A, et al. Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatrics 2004; 114:584.
  140. Price CS, Thompson WW, Goodson B, et al. Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism. Pediatrics 2010; 126:656.
  141. Thompson WW, Price C, Goodson B, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 2007; 357:1281.
  142. Schechter R, Grether JK. Continuing increases in autism reported to California's developmental services system: mercury in retrograde. Arch Gen Psychiatry 2008; 65:19.
  143. Classen JB, Classen DC. Clustering of cases of type 1 diabetes mellitus occurring 2-4 years after vaccination is consistent with clustering after infections and progression to type 1 diabetes mellitus in autoantibody positive individuals. J Pediatr Endocrinol Metab 2003; 16:495.
  144. Classen DC, Classen JB. The timing of pediatric immunisation and the risk of insulin-dependent diabetes mellitus. Infectious Dis Clin Pract 1997; 6:449.
  145. Morgan E, Halliday SR, Campbell GR, et al. Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia 2016; 59:237.
  146. Graves PM, Barriga KJ, Norris JM, et al. Lack of association between early childhood immunizations and beta-cell autoimmunity. Diabetes Care 1999; 22:1694.
  147. Blom L, Nyström L, Dahlquist G. The Swedish childhood diabetes study. Vaccinations and infections as risk determinants for diabetes in childhood. Diabetologia 1991; 34:176.
  148. Levitsky LL. Childhood immunizations and chronic illness. N Engl J Med 2004; 350:1380.
  149. Smith MJ, Ellenberg SS, Bell LM, Rubin DM. Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship to MMR immunization rates in the United States. Pediatrics 2008; 121:e836.